Article: Cytori Reports Publication of Cardiovascular Preclinical Study; Adipose Stem & Regenerative Cells Improve Function in Heart Attack Model.

Cytori (NASDAQ: CYTX) announced publication of the first preclinical study to demonstrate adipose-derived stem and regenerative cells (ADRCs) significantly improved cardiac function after a heart attack. This preclinical cardiac cell therapy study was reported online ahead of print in the International Journal of Cardiology. The study was funded by Cytori Therapeutics and conducted at Tulane University (see also Cytori Therapeutics).

"Treatment of cardiovascular disease, which places one of the greatest burdens on our healthcare system, could be revolutionized by cell therapy," said Marc H. Hedrick, M.D., president of Cytori. "We observed a statistically ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!